Stephen L. Chan

Active 1993–2026

188
Papers
33,756
Citations
84
h-index
172
i10-index

Citations

Citations per year for Stephen L. Chan1993: 2 citations1994: 3 citations1995: 3 citations1997: 2 citations1998: 1 citations1999: 2 citations2000: 4 citations2001: 13 citations2002: 4 citations2003: 14 citations2004: 11 citations2005: 15 citations2006: 10 citations2007: 7 citations2008: 20 citations2009: 32 citations2010: 28 citations2011: 40 citations2012: 33 citations2013: 64 citations2014: 68 citations2015: 122 citations2016: 112 citations2017: 165 citations2018: 248 citations2019: 1,024 citations2020: 1,586 citations2021: 1,858 citations2022: 1,624 citations2023: 1,481 citations2024: 2,559 citations2025: 1,478 citations2026: 15 citations1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 3,362 citing papers, 24.6% of this breakdownUnited States: 2,285 citing papers, 16.7% of this breakdownJapan: 801 citing papers, 5.9% of this breakdownItaly: 700 citing papers, 5.1% of this breakdownGermany: 605 citing papers, 4.4% of this breakdownUnited Kingdom: 538 citing papers, 3.9% of this breakdownHong Kong: 473 citing papers, 3.5% of this breakdownFrance: 457 citing papers, 3.3% of this breakdownSouth Korea: 429 citing papers, 3.1% of this breakdownSpain: 391 citing papers, 2.9% of this breakdownTaiwan: 375 citing papers, 2.7% of this breakdownCanada: 345 citing papers, 2.5% of this breakdown
0%24.6%Other 21.4%

Fields

  • Medicine67.6%
  • Biochemistry, Genetics and Molecular Biology25.2%
  • Immunology and Microbiology3.9%
  • Engineering0.8%
  • Computer Science0.4%
  • Neuroscience0.4%
  • Other1.7%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis12.9%
  • Cancer Immunotherapy and Biomarkers6.1%
  • Cancer Genomics and Diagnostics4.5%
  • Liver Disease Diagnosis and Treatment4.5%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.4%
  • Hepatitis B Virus Studies2.5%
  • Other65.1%

Coauthors

All papers

Open in search
  1. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruno Sangro - NEJM Evidence 2022 cited by 1,432

  2. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov and 38 more - The Lancet 2023 cited by 679

  3. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita - The Lancet Oncology 2018 cited by 2,536

  4. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025

  5. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 1,819

  6. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 2,337

  7. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 2,755

  8. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 cited by 522

  9. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa and 103 more - Annals of Oncology 2024 cited by 312

  10. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

    Authors: , , , , - Journal of Hepatology 2020 cited by 565

  11. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 779

  12. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

    Authors: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 809

  13. Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

    Authors: , , , , , , , , , , - Liver International 2019 cited by 592

  14. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 152

  15. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

    Authors: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 755

  16. Systemic treatment of hepatocellular carcinoma: An EASL position paper

    Authors: , , , , - Journal of Hepatology 2021 cited by 396

  17. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 400

  18. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2021 cited by 162

  19. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2023 cited by 144

  20. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

    Authors: , , , , , , , , , , , - Liver Cancer 2020 cited by 307

  21. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julien Calderaro, Stefano Caruso, Stefano Caruso, A. García, Stephen L. Chan, Stephen Lam Chan, Antonio D'Alessio, Alba Díaz, Antonia Digklia, Jean‐François Dufour, Jean-François Dufour, Narmin Ghaffari Laleh, Narmin Ghaffari Laleh, Purva Gopal, Rondell P. Graham, Alexandra Heurgué, Massimo Iavarone, Mercedes Iñarrairaegui, Jakob Nikolas Kather, Jakob Nikolas Kather, Ismaïl Labgaa, Sonia Lameiras, Patricia Legoix, Marie Lequoy, Howard H.W. Leung, Howard Ho-Wai Leung, Marco Maggioni, Marco Maggioni, Juan Ignacio Marín, Guillermo Mendoza-Pacas, Sophie Michalak, Beatriz Mínguez, Omar S. M. El Nahhas, Omar S M El Nahhas, Pooja Navale, Massih Ningarhari, Massih Ningarhari, Valérie Paradis, Jean–Michel Pawlotsky, Jean-Michel Pawlotsky, Riccardo Perbellini, Riccardo Perbellini, Simon Peter, David James Pinato, Pompilia Radu, Hélène Regnault, María Reig, Maria Reig, Mohamed Rela, Lorenza Rimassa, Margherita Rimini, María Teresa Salcedo, María Teresa Salcedo, Bruno Sangro, Christine Sempoux, Tung‐Hung Su, Callie Torres, Nguyen H. Tran, Eric Trépo, Marı́a Varela, Gontran Verset, Gontran Verset, Arndt Vogel, Dominique Wendum, Qinghe Zeng, Qinghe Zeng, Marianne Ziol, Léa Bruges, Viviane Gnemmi, Jean-Charles Nault and 23 more - The Lancet Oncology 2023 cited by 109

  22. Epigenetic analysis of cell-free DNA by fragmentomic profiling

    Authors: , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 148

  23. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2016 cited by 323

  24. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin

    Authors: , , , , , , , , , , , , , , , , - Genome Research 2019 cited by 263